ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, ...
Cytokinetics started at buy by Stifel, aficamten highlighted
Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...
Hold Rating Given for Zanzalintinib Based on STELLAR-001 Trial Outcomes
Stifel Nicolaus analyst Stephen Willey has maintained their neutral stance on EXEL stock, giving a Hold rating today.Invest with Confidence: ...
Stifel Nicolaus Keeps Their Buy Rating on ioneer Limited (GSCCF)
Stifel Nicolaus analyst Cole McGill maintained a Buy rating on ioneer Limited (GSCCF – Research Report) today and set a price target of A$0.40.
Stifel Nicolaus Lowers Shake Shack (NYSE:SHAK) Price Target to $110.00
Shake Shack (NYSE:SHAK – Get Free Report) had its price objective lowered by equities researchers at Stifel Nicolaus from ...
Stifel Nicolaus Forecasts Strong Price Appreciation for Schneider National (NYSE:SNDR) Stock
Schneider National (NYSE:SNDR – Get Free Report) had its price target boosted by research analysts at Stifel Nicolaus from ...
Nasdaq14d
Structure Therapeutics initiated with a Buy at Stifel
Stifel initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $50 price target Structure aims to expand the reach of metabolic treatments across the large, heterogeneous obesity ...
Yahoo Finance15d
Stifel Nicolaus Raises Astera Labs (ALAB) Price Target, Cites AI Infrastructure Benefits
We recently published a list of Top 10 AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Astera Labs, Inc. (NASDAQ:ALAB) stands against other AI stocks on Wall ...